{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lung+Cancer&page=30&q=small+cell+lung+cancer", "query": { "q": "small cell lung cancer", "condition": "Lung Cancer", "page": 30 }, "page_size": 10 }, "pagination": { "page": 30, "page_size": 10, "total_count": 4378, "total_pages": 438, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lung+Cancer&page=31&q=small+cell+lung+cancer&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lung+Cancer&page=29&q=small+cell+lung+cancer&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T10:00:03.183Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02920476", "title": "TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Lung Carcinoma (UF-STO-LUNG-003)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Squamous Cell Lung Carcinoma" ], "interventions": [ { "name": "TAS-102", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 4, "start_date": "2017-07-19", "completion_date": "2021-08-14", "has_results": true, "last_update_posted_date": "2022-06-23", "last_synced_at": "2026-10-16T10:00:03.183Z", "location_count": 1, "location_summary": "Gainesville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02920476" }, { "nct_id": "NCT01752400", "title": "AUY922 for Advanced ALK-positive NSCLC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "AUY922", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2013-01", "completion_date": "2017-11", "has_results": true, "last_update_posted_date": "2018-03-29", "last_synced_at": "2026-10-16T10:00:03.183Z", "location_count": 4, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01752400" }, { "nct_id": "NCT00578149", "title": "Bevacizumab and Carboplatin/Paclitaxel and Radiation in Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2006-05", "completion_date": "2007-08", "has_results": false, "last_update_posted_date": "2007-12-21", "last_synced_at": "2026-10-16T10:00:03.183Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00578149" }, { "nct_id": "NCT00408226", "title": "Safety Study of MKC-1 Combined With Pemetrexed to Treat Advanced Cancer and Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Cancer", "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "MKC-1", "type": "DRUG" }, { "name": "pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CASI pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2006-10", "completion_date": "2012-01", "has_results": false, "last_update_posted_date": "2012-01-20", "last_synced_at": "2026-10-16T10:00:03.183Z", "location_count": 4, "location_summary": "Indianapolis, Indiana • Iowa City, Iowa • Seattle, Washington + 1 more", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Seattle", "state": "Washington" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00408226" }, { "nct_id": "NCT00290017", "title": "Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung", "Lung Cancer", "Neoplasms, Lung", "Neoplasms, Pulmonary" ], "interventions": [ { "name": "talabostat", "type": "DRUG" }, { "name": "pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Point Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 400, "start_date": "2006-02", "completion_date": null, "has_results": false, "last_update_posted_date": "2007-06-08", "last_synced_at": "2026-10-16T10:00:03.183Z", "location_count": 101, "location_summary": "Huntsville, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 84 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Burbank", "state": "California" }, { "city": "Fountain Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00290017" }, { "nct_id": "NCT07094204", "title": "A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Non-Small-Cell Lung Cancer", "Pancreatic Ductal Adenocarcinoma", "Colorectal Cancer" ], "interventions": [ { "name": "ASP5834", "type": "DRUG" }, { "name": "panitumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 404, "start_date": "2025-07-25", "completion_date": "2029-04-30", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-16T10:00:03.183Z", "location_count": 11, "location_summary": "Santa Monica, California • Atlanta, Georgia • Jefferson, Louisiana + 8 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Jefferson", "state": "Louisiana" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT07094204" }, { "nct_id": "NCT02785952", "title": "Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Recurrent Squamous Cell Lung Carcinoma", "Stage IV Squamous Cell Lung Carcinoma AJCC v7" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 275, "start_date": "2015-12-29", "completion_date": "2027-04-01", "has_results": true, "last_update_posted_date": "2026-06-09", "last_synced_at": "2026-10-16T10:00:03.183Z", "location_count": 1201, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 735 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02785952" }, { "nct_id": "NCT04740047", "title": "Cios Mobile 3D Spin for Robotic Bronchoscopy", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pulmonary Nodule, Solitary", "Pulmonary Cancer", "Lung Cancer", "Lung Cancer, Nonsmall Cell", "Lung Adenocarcinoma" ], "interventions": [ { "name": "Ion Endoluminal System", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2021-02-01", "completion_date": "2023-05-22", "has_results": false, "last_update_posted_date": "2024-06-27", "last_synced_at": "2026-10-16T10:00:03.183Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04740047" }, { "nct_id": "NCT05722847", "title": "Risk Stratification for Patients With Hospital-diagnosed Advanced Lung Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lung Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2023-03-14", "completion_date": "2025-05-02", "has_results": false, "last_update_posted_date": "2025-05-25", "last_synced_at": "2026-10-16T10:00:03.183Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05722847" }, { "nct_id": "NCT04585815", "title": "Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Sasanlimab Prefilled syringe", "type": "DRUG" }, { "name": "Encorafenib", "type": "DRUG" }, { "name": "Binimetinib", "type": "DRUG" }, { "name": "Sasanlimab", "type": "DRUG" }, { "name": "Axitinib", "type": "DRUG" }, { "name": "SEA-TGT", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2020-11-10", "completion_date": "2024-10-29", "has_results": true, "last_update_posted_date": "2026-01-09", "last_synced_at": "2026-10-16T10:00:03.183Z", "location_count": 43, "location_summary": "Duarte, California • Encinitas, California • Fresno, California + 25 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Encinitas", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04585815" } ] }